Standout Papers

Phase III Study of Afatinib or Cisplatin... 1996 2026 2006 2016 2.4k
  1. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations (2013)
    Lecia V. Sequist, James Chih‐Hsin Yang et al. Journal of Clinical Oncology
  2. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer (2015)
    Pasi A. Jänne, James Chih‐Hsin Yang et al. New England Journal of Medicine
  3. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial (2012)
    Vincent A. Miller, Vera Hirsh et al. The Lancet Oncology
  4. Cell Growth Arrest and Induction of Cyclin-Dependent Kinase Inhibitor p21 WAF1/CIP1 Mediated by STAT1 (1996)
    Y. Eugene Chin, Motoo Kitagawa et al. Science
  5. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study (2020)
    Lecia V. Sequist, Ji‐Youn Han et al. The Lancet Oncology
  6. Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC (2023)
    Masahiro Tsuboi, Roy S. Herbst et al. New England Journal of Medicine
  7. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC (2021)
    Roy S. Herbst, Edward B. Garon et al. Journal of Thoracic Oncology
  8. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON (2022)
    Ryan J. Hartmaier, Aleksandra Markovets et al. Cancer Discovery

Immediate Impact

8 by Nobel laureates 10 from Science/Nature 101 standout
Sub-graph 1 of 19

Citing Papers

New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
Photothermal Nanomaterials: A Powerful Light-to-Heat Converter
2023 Standout
27 intermediate papers

Works of Wu‐Chou Su being referenced

Handheld energy-efficient magneto-optical real-time quantitative PCR device for target DNA enrichment and quantification
2016
A New Photothermal Therapeutic Agent: Core‐Free Nanostructured AuxAg1−x Dendrites
2008
and 15 more

Author Peers

Author Last Decade Papers Cites
Wu‐Chou Su 8845 8430 6390 356 16.6k
Benjamin Solomon 12283 13677 6482 407 20.0k
Chandra P. Belani 13125 13911 6250 454 21.6k
Gary K. Schwartz 11072 7272 8340 436 20.5k
Julian R. Molina 10277 7942 6099 211 17.8k
Ramaswamy Govindan 8925 9583 5101 465 17.6k
Kenneth J. O’Byrne 12402 10276 8206 586 23.0k
Dong‐Wan Kim 13564 12389 4383 356 20.9k
Luis Paz‐Ares 12823 11087 7419 681 22.1k
Stefan Sleijfer 6993 4582 4150 378 13.2k
Sun Young Rha 7734 8837 6404 715 17.9k

All Works

Loading papers...

Rankless by CCL
2026